Pathway | Specific target | Drugs |
EGF/MAPK | EGFR (mAb) | Cetuximab, Panitumumab |
EGFR (TKI) | Erlotinib, Gefitinib | |
KRAS | Tipifarnib, Lonafarnib | |
BRAF | Sorafenib, PLX4032, XL281 | |
MEK | Selumetinib | |
PI3K | PI3K | BKM120, BGT226, XL147, GDC-0941 |
mTOR | Everolimus, XL765 | |
AKT | Perifosine | |
WNT | Resveratrol | |
TGFβ | TGFβ2 | AP 12009 |
VEGF | VEGF | Bevacizumab |
VEGFR | Vatalanib, AMG706, Pazopanib, Cediranib | |
HGF | HGF mAb | AMG102 |
IGF | IGF-1 mAb | AMG479, IMC-A12 |
EGF, epidermal growth factor; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; TGFβ, transforming growth factor β; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.